AIM Immunotech Inc.
https://aimimmuno.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AIM Immunotech Inc.
Orasis Prepares To Battle AbbVie In Presbyopia
The privately held firm got FDA approval for Qlosi, which like AbbVie’s Vuity is a low-dose formulation of pilocarpine for age-related near vision loss. Launch is planned for early 2024.
Finance Watch: Adlai Nortye Raises $97.5m In IPO, Brings US Total To 18
Public Company Edition: Cancer-focused Adlai Nortye launched a concurrent initial public offering and private placement, while four other drug developers announced or completed SPAC mergers. Also, Sobi grossed $540m in a rights issue and Immunovant followed early data with a $450m FOPO.
Finance Watch: ReCode’s Series B Mega-Round Grows Again With $50m Boost
Private Company Edition: ReCode’s series B venture capital round grew for a third time, now totaling $260m for precision genetic medicines. Also, DalCor closed an $80m series D, manufacturer Nephron amassed $350m, Hyku launched with a $56m seed financing and Magnet emerged with $50m.
With Strong Anti-Inflammatory Candidate In Hand, Abivax Execs Carve A Path Forward
With a strong late-stage anti-inflammatory molecule in its pipeline, the challenge for Abivax is to garner the funds to take its obefazimod program forward. To that end, the company is continuing to do a major overhaul of personnel and is sharpening its corporate vision.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Pharmaceuticals
- Contract Manufacturing Organization
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Other Names / Subsidiaries
-
- Hemispherx Biopharma, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice